vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $982.9M, roughly 1.1× APTARGROUP, INC.). APTARGROUP, INC. runs the higher net margin — 7.4% vs -127.8%, a 135.2% gap on every dollar of revenue. On growth, APTARGROUP, INC. posted the faster year-over-year revenue change (10.8% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $53.3M). Over the past eight quarters, APTARGROUP, INC.'s revenue compounded faster (3.9% CAGR vs 1.3%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
ATR vs PRGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $982.9M | $1.1B |
| Net Profit | $72.8M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | 10.9% | -116.0% |
| Net Margin | 7.4% | -127.8% |
| Revenue YoY | 10.8% | -2.5% |
| Net Profit YoY | -7.5% | -3093.9% |
| EPS (diluted) | $1.12 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $982.9M | — | ||
| Q4 25 | $962.7M | $1.1B | ||
| Q3 25 | $961.1M | $1.0B | ||
| Q2 25 | $966.0M | $1.1B | ||
| Q1 25 | $887.3M | $1.0B | ||
| Q4 24 | $848.1M | $1.1B | ||
| Q3 24 | $909.3M | $1.1B | ||
| Q2 24 | $910.1M | $1.1B |
| Q1 26 | $72.8M | — | ||
| Q4 25 | $74.3M | $-1.4B | ||
| Q3 25 | $127.9M | $7.5M | ||
| Q2 25 | $111.7M | $-8.4M | ||
| Q1 25 | $78.8M | $-6.4M | ||
| Q4 24 | $100.9M | $-44.4M | ||
| Q3 24 | $100.0M | $-21.0M | ||
| Q2 24 | $90.5M | $-108.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% |
| Q1 26 | 10.9% | — | ||
| Q4 25 | 11.0% | -116.0% | ||
| Q3 25 | 14.2% | 7.0% | ||
| Q2 25 | 14.9% | 4.3% | ||
| Q1 25 | 12.8% | 4.5% | ||
| Q4 24 | 14.2% | 10.0% | ||
| Q3 24 | 15.2% | 7.4% | ||
| Q2 24 | 13.8% | -2.5% |
| Q1 26 | 7.4% | — | ||
| Q4 25 | 7.7% | -127.8% | ||
| Q3 25 | 13.3% | 0.7% | ||
| Q2 25 | 11.6% | -0.8% | ||
| Q1 25 | 8.9% | -0.6% | ||
| Q4 24 | 11.9% | -3.9% | ||
| Q3 24 | 11.0% | -1.9% | ||
| Q2 24 | 9.9% | -10.2% |
| Q1 26 | $1.12 | — | ||
| Q4 25 | $1.13 | $-10.23 | ||
| Q3 25 | $1.92 | $0.05 | ||
| Q2 25 | $1.67 | $-0.06 | ||
| Q1 25 | $1.17 | $-0.05 | ||
| Q4 24 | $1.48 | $-0.32 | ||
| Q3 24 | $1.48 | $-0.15 | ||
| Q2 24 | $1.34 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $229.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $2.9B |
| Total Assets | $5.1B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $229.5M | — | ||
| Q4 25 | $409.5M | — | ||
| Q3 25 | $264.8M | $432.1M | ||
| Q2 25 | $169.8M | $454.2M | ||
| Q1 25 | $136.8M | $409.9M | ||
| Q4 24 | $226.2M | $558.8M | ||
| Q3 24 | $327.9M | $1.5B | ||
| Q2 24 | $223.9M | $542.8M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | — | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — |
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.7B | $2.9B | ||
| Q3 25 | $2.8B | $4.4B | ||
| Q2 25 | $2.7B | $4.5B | ||
| Q1 25 | $2.5B | $4.4B | ||
| Q4 24 | $2.5B | $4.3B | ||
| Q3 24 | $2.5B | $4.6B | ||
| Q2 24 | $2.4B | $4.5B |
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.3B | $8.5B | ||
| Q3 25 | $5.1B | $10.1B | ||
| Q2 25 | $4.9B | $10.1B | ||
| Q1 25 | $4.5B | $9.8B | ||
| Q4 24 | $4.4B | $9.6B | ||
| Q3 24 | $4.6B | $11.2B | ||
| Q2 24 | $4.5B | $10.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.4M |
| Free Cash FlowOCF − Capex | $53.3M | $148.6M |
| FCF MarginFCF / Revenue | 5.4% | 13.4% |
| Capex IntensityCapex / Revenue | 6.7% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.0M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $183.7M | $175.4M | ||
| Q3 25 | $177.6M | $51.7M | ||
| Q2 25 | $126.0M | $75.9M | ||
| Q1 25 | $82.7M | $-64.5M | ||
| Q4 24 | $178.2M | $312.6M | ||
| Q3 24 | $229.3M | $42.2M | ||
| Q2 24 | $143.6M | $9.5M |
| Q1 26 | $53.3M | — | ||
| Q4 25 | $96.9M | $148.6M | ||
| Q3 25 | $114.3M | $29.8M | ||
| Q2 25 | $62.5M | $56.7M | ||
| Q1 25 | $25.9M | $-90.0M | ||
| Q4 24 | $112.2M | $274.9M | ||
| Q3 24 | $162.7M | $15.1M | ||
| Q2 24 | $75.4M | $-18.9M |
| Q1 26 | 5.4% | — | ||
| Q4 25 | 10.1% | 13.4% | ||
| Q3 25 | 11.9% | 2.9% | ||
| Q2 25 | 6.5% | 5.4% | ||
| Q1 25 | 2.9% | -8.6% | ||
| Q4 24 | 13.2% | 24.2% | ||
| Q3 24 | 17.9% | 1.4% | ||
| Q2 24 | 8.3% | -1.8% |
| Q1 26 | 6.7% | — | ||
| Q4 25 | 9.0% | 2.4% | ||
| Q3 25 | 6.6% | 2.1% | ||
| Q2 25 | 6.6% | 1.8% | ||
| Q1 25 | 6.4% | 2.4% | ||
| Q4 24 | 7.8% | 3.3% | ||
| Q3 24 | 7.3% | 2.5% | ||
| Q2 24 | 7.5% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.47× | — | ||
| Q3 25 | 1.39× | 6.89× | ||
| Q2 25 | 1.13× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 1.77× | — | ||
| Q3 24 | 2.29× | — | ||
| Q2 24 | 1.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
Segment breakdown not available.
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
